updat model
summari due report result
lower forecast ahead report due
anticip near-term headwind particularli
medic devic busi increment fx headwind
forecast sale adjust oper ep
consensu forecast
respect lower sale
forecast adjust oper ep
estim updat model also
assum catch sale instead
assum pandemic-rel lost sale
recoup lower sales/ep forecast
adjust oper
next year respect new forecast assum
major share repurchas meaning activ
possibl given jnj current share price recent
pull back asset valuat addit expect
greater flexibl dial up/down spend
necessari help manag bottom-lin growth overal
believ jnj diversifi busi uncertain time help
compani weather near-term headwind strong
pipelin posit underli growth momentum bode well
resum growth post histori show share
outperform peer last three
recess lower price target
base new ep estim
lower forecast lower total sale
forecast adjust oper sale
growth chang larg reflect reduc sale forecast
medic devic busi due impact lesser
extent increment fx headwind rais us pharma sale
forecast base qtd iqvia trend
caveat potenti rebating/discount chang may
reflect iqvia data see potenti upsid consum
nielsen data show signific uptick sale march specif
to-dat nielsen data point yr/yr growth us
consum compar estim recent histor
growth low- mid-singl digit also lower ep
estim
lower forecast headwind
increment fx pressur expect lower guidanc
lower sale forecast adjust
oper ep estim report
new forecast assum signific pressur jnj medic
devic busi may model assum recoveri
lost procedures/sal meaning share buy-back
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
compani data secur llc estim reuter
lower price target lower price target base new
ep estim price-to-earnings base sum-of-the-part analysi peer group valuat
assum jnj consum busi trade in-lin peer pharma busi trade
premium medic devic trade discount peer
share trade histor averag share current trade ntm consensu
earn new ep estim histor forward valuat averag
figur stock current trade discount
 histor averag premium diversifi
busi believ defens posit weather near-term uncertain market
thu warrant trade closer histor valuat rang slightli premium
note last three recess share outperform peer group broader
figur ntm price-to-earnings valuat
figur ntm price-to-earnings valuat
lower forecast report result lower sale
forecast adjust oper growth sale reduct larg reflect
assumpt neg impact jnj medic devic
increment fx headwind partli off-set net increas us pharma sale forecast
although chang consum forecast to-dat nielsen data point signific sale increas
march perhap due pandem safeti stock repres potenti upsid expect
ep estim lower believ sale headwind materi
rel late quarter compani limit flexibl dial back associ spend
recess recess recess hc equip suppli na na na na na na ew na na na na na na na na na na na snn na na na med-tech averag factset secur llc medic technolog
expect declin across jnj medic devic busi due estim
jnj med-tech sale total sale tie elect procedur
postpon pandem dilig suggest mani elect procedur
could see orthoped volum declin pandem lower medic
devic sale forecast adjust oper growth assum
pandem headwind feb/ china rest world includ us decreas
sale forecast repres nearli headwind overal sale growth
iqvia data suggest stronger expect perform sever key us drug base
iqvia analysi rais us sale forecast stelara xarelto zytiga uptravi
aggreg partli off-set lower estim imbruvica chang
forecast remicad erleada iqvia analysi point potenti modest upsid note
biosimilar eros remicad procrit gener eros zytiga tracleer continu
creat uncertainti potenti adjust captur iqvia inventori prior period
price adjust etc forecast us pharmaceut sale yr/yr growth
in-lin growth global estim pharmaceut sale ex-fx
growth detail us product tracker analysi start page
consum organ sale growth vs us estim consum
sale growth slight deceler howev analysi nielsen data
point sequenti growth us consum growth period
figur suggest possibl consum safeti stock nielsen report us consum
sale growth trend similarli time notabl quarterli variat due part
aggreg weekli nielsen data figur although chang forecast see potenti
upsid consum sale forecast ww consum sale includ us
nielsen sale base aggreg data
organ growth ex-fx compani report secur llc estim organ growth adjust fx acquisitions/divestitur sell day prior price adjust pharma venezuela/anima exit vc stocking/destock cardiovascular cerenovu neurovascular intervent solut start diabet adjust anima exit impact medic devic busi adjust potenti impact amo acqusit includ ex-fx growth rate atln acquisit includ ex-fx growth rate key busi growthnielsen estimate report organ growth estimate johnson johnson
nielsen sale base aggreg data
lower estim increment fx headwind lower
sale forecast report adjust oper ep estim
report ex-fx headwind account sale
reduct increment fx headwind repres lower sale partli off-set
net higher us pharma sale keep mind extra sell week add
growth net impact sku ration consum convers
physician survey work point like catch mani procedur
categori month follow pandem forecast conserv assum catch
given uncertainti durat pandem forecast ex-fx sale
growth compris nearli underli growth catch sale
pandemic-rel lost sale model assum meaning share repurchas would
repres upsid forecast
jnj med-tech busi expect face signific near-term pandem headwind like
hardest hit jnj medic devic busi anticip signific near-term pressur
stem due postpon elect procedur lower
med-tech sale estim adjust oper declin yr/yr expect
hardest hit pandem reduc sale return normal oper start
june forecast continu includ benefit extra ship day forecast
assum lost procedur reschedul may prove conserv
consum busi assum materi impact stem
outbreak consum media report increas purchas over-the-counter product like tylenol safeti
stock review nielsen data four week end also point signific
sale increas compar four week end prior year sequenti growth much
modest mid-singl digit could see safeti stock purchas continu end
march april help boost perform remain seen howev posit
effect revers back half year pandem subsid addit recal
plan ration certain sku consum busi reduc total sale growth
consum growth year new patient start
medicin may delay expect patient remain therapi potenti stock
extra prescript pandem analysi weekli im data sever key drug point
continu strong perform
assumpt behind analysi term time assum impact jan-
feb sale china total sale mid-march may sale us rest
world analysi assum catch sale perhap somewhat conserv assumpt
lost sale recoup new sale forecast
assum similar growth rate lower revenu base plu
pandemic-rel catch beyond assum prior top-lin growth rate remain rel
unchang impact assum corpor oper margin cap
expect compani greater abil dial spend account reduc
top-lin assum corpor margin cap
expect lower guidanc januari guid adjust oper sale
growth ex-fx acquisitions/divestitur report growth report ep
growth midpoint rang top-lin outlook includ benefit
extra ship day net sku ration consum expect manag lower
guidanc due near-term headwind uncertainti pandem increment fx pressur
cfo recent quot articl go precis wrong
guidanc updat call note peer includ snn
rel higher exposur elect procedur recent withdrawn guidanc
capit deploy possibl buy back share strateg deal cash
balanc sheet current depress stock level could see announc new stock buy-back
program current stock price close estim everi share
repurchas could add jnj ep ep growth annual addit
period rel depress asset valuat could see opportun well-
financ compani like pursu strateg neither meaning stock buy-back
reflect current forecast remain solid financi posit net debt
gener free cash-flow year expect compani continu gener strong
cash-flow flexibl return capit sharehold via dividend share
recent materi updat talc opioid litig talc litig continu await
decis daubert hear held juli continu expect time
judg decid whether plaintiff reliabl scientif proof regard talc-ovarian cancer link
recal earli januari larg analysi nih nation institut publish jama
journal american medic associ found evid link babi powder ovarian cancer
posit defens talc case understand major
ovarian cancer case opioid case continu believ damage/settl like
manag given strong balanc sheet compani current await process
settlement stage could happen
estprev compani report secur llc organ growth report ex-fx adjust sell day differ venezuela impact prior period price adjust johnson johnson
maintain us remicad sale forecast estim us remicad ex-export sale
yr/yr declin slightli extrapol iqvia sale qtd
jan-feb iqvia sale fell yr/yr declin chang forecast report us remicad
sale declin sever iqvia sale declin recent quarter perhap due
increment rebating/discount price adjust report us remicad sale fell
averag yr/yr vs averag iqvia sale declin period
biosimilar remicad continu slow climb iqvia sale show biosimilar remicad sale continu
inch slow increas averag averag figur howev
jnj remicad remain leader nearli dollar sale even though biosimilar competit
began year ago trail averag remicad iqvia sale fallen
exit end feb appear direct
consist eros report sale due increas rebat discount
biosimilar procrit uptak remain ahead biosimilar remicad first year sale pfe
biosimilar procrit retacrit launch ramp faster initi biosimilar remicad launch
first year specif retacrit iqvia sale climb jan jul
feb repres total brand/biosimilar procrit sale
comparison biosimilar sale account total brand/biosimilar remicad sale month post-
launch forecast us procrit sale yr/yr declin compar declin
extrapol iqvia sale forecast seem reason extrapol quarterli iqvia sale
declin wors report sale declin
spravato balversa uptak continu data remain limit new spravato indic
expect spravato treatment resist depress balversa bladder cancer
approv earli drug limit distribut thu iqvia data like under-captur
actual sale ramp spravato extrapol iqvia sale total
estim spravato trx averag per week recent
averag per week expect fda approv spravato rapid reduct
depress symptom patient suicid ideat later year balversa extrapol iqvia
sale total slightli estim chang
forecast either product given magnitud differ lack sale report
maintain us darzalex sale forecast estim us darzalex sale
yr/yr growth extrapol iqvia sale forecast ww
darzalex sale ex-fx growth yr/yr forecast ww darzalex sale
yr/yr low-end genmab estim year expect
darzalex growth driven increas front-lin use transplant elig inelig
patient well fda approv subq darzalex formul around mid-year new formul
expect signific reduc infus time thu expand capac access accord
brandimpact darzalex share front-lin mm multipl myeloma rose feb
past month approv maia cassiopeia front-lin use jun sep
respect figur line use darzalex share reach feb vs sep behind
market leader revlimid share figur line darzalex remain market leader
share feb sep follow revlimid share figur darzalex
share overal mm market rel stabl past month brandimpact survey
lower us imbruvica sale forecast decreas us imbruvica revenu
estim impli end-us sale within
extrapol iqvia sale rang impli revenu
ww imbruvica revenu forecast fall amount translat revenu
rx perspect roll imbruvica trx volum
grew weekli exce figur call reiter imbruvica
remain clear market share leader cll across line therapi
yr/yr slightli extrapol iqvia sale invokana
franchis volum fell jan/feb improv declin figur
similarli iqvia data first two week show low teen rx volum declin figur
invokana franchis nrx share class fallen jan stabil around
mid-teen recent month competitor boehring ingelheim lli jardian franchis remain
leader categori nrx share nrx volum growth feb figur
categori nrx growth approxim ytd mid-teen averag growhth
increas zytiga sale estim increas us zytiga sale forecast
declin yr/yr compar extrapol iqvia sale brand
zytiga keep mind report brand gener zytiga line zytiga nrx
volum yr/yr jan/feb compar declin follow entri
gener competit decemb howev partli offset declin strength gener
zytiga continu hold share among gener follow apotex share
sun pharma share
modest upsid potenti us erleada sale forecast estim us erleada sale
slightli extrapol iqvia sale chang forecast given
modest magnitud differ year post launch erleada us sale annual
base feb iqvia sale roughli doubl past month monthli
erleada trx nrx volum increas respect past year erleada
help slow eros jnj prostat cancer franchis erleada zytiga volum
jan/feb compar declin zytiga alon erleada label expand late includ
metastat castration-sensit prostat cancer mcspc help broaden adopt
increas xarelto sale forecast rais us xarelto sale estim
growth yr/yr although new forecast extrapol iqvia sale rang
modest reflect volum growth jan/feb competit market
dynam tend drive price pressur xarelto sale either declin remain flat yr/yr
past six quarter despit single-digit rx volum growth period cad/pad
coronari arteri disease/peripher arteri diseas indic contribut posit franchis
growth overal xarelto rx volum growth deceler high-singl low-singl digit figur
iqvia trend suggest xarelto cad/pad ad overal xarelto
franchis growth feb competitor eliqui maintain lead among noac share
m/m follow xarelto share m/m past year xarelto lost
share eliqui gain share figur noac account
oral anticoagul nrx two year ago figur
maintain us invega sustenna/trinza sale forecast estim us stelara/trinza
sale grow yr/yr within extrapol iqvia sale rang
chang estim note report stelara/trinza sale growth exceed iqvia
trinza risperd consta report sale growth differ meaning iqvia sale growth
report vs flat iqvia report vs iqvia report vs
iqvia figur comfort growth assumpt vs iqvia
sale growth jan/feb believ may anomali iqvia data calcul
sourc depress sale jnj laia franchis sinc apr result yr/yr
sale declin vs histor growth high-singl double-digit us laia market
maintain nrx market share past month due declin
risperd consta ostuka abilifi maintena hold share yr/yr aristada
increas us stelara sale forecast increas us stelara sale
yr/yr growth closer extrapol iqvia sale rang stelara
iqvia sale grew jan/feb rel stabl compar
deceler modest growth deceler may partli due strong uptak
tremfya figur stelara fda approv ulcer coliti uc oct repres
increment growth tailwind eu approv sep stelara trx volum specialti show
crohn key growth driver growth volum written gastroenterolog specialist
past year volum rheumatologist grew past year partli off-set
declin volum written dermatologist perhap reflect cannib tremfya
dermatologist account stelara trx vs start write
vs earli expect mix gi-written stelara rx continu increas
uptak new uc indic also treat
maintain us tremfya sale forecast estim us tremfya sale
within extrapol iqvia sale rang report sale declin percentag
iqvia sale past year suggest like increas discount rebat activ
year market tremfya iqvia sale base jan/feb data track closer lli
taltz annual sale trail nvss cosentyx annual sale time
post-launch cosentyx iqvia sale annual taltz iqvia sale annual weekli
tremfya trx volum continu track ahead stelara remain behind cosentyx track
closer taltz time post-launch figur continu see tremfya import
growth driver jnj pharma busi
maintain us simponi/aria sale estim forecast us simponi/aria sale
slightli extrapol iqvia sale forecast impli yr/yr
growth in-lin jan/feb iqvia sale growth jan/feb simponi iqvia sale fell
yr/yr aria iqvia sale rose togeth drive franchis growth figur
rais us uptravi sale forecast increas us uptravi sale estim
yr/yr growth closer extrapol iqvia sale
figur chang us tracleer sale estim slightli extrapol
iqvia sale figur recent entri gener competit may
chang rebat accrual inventori adjust could depress report sale opsumit us
sale estim extrapol iqvia sale figur howev
chang forecast report opsumit sale declin percentag iqvia sale
suggest potenti increas rebat activ may persist note greater
variabl report iqvia sale quarter quarter pah pulmonari arteri
hypertens product compar product track via iqvia
analysi independ arriv secur llc basi data
inform iqvia respons relianc recipi either data analys
mm imsimsimsour us split iqvia nation sale perspect compani report secur llc estim sale estim base commentari iqvia data forecast us imbruvica sale assum record end-us sale report consist third month perform prior quarter assum march im sale repres medic technolog
compris mostli pfe/celltrion inflectra
figur darzalex penetr increas line multipl myeloma market
figur darzalex remain line multipl myeloma market
figur darzalex remain market share leader line multipl myeloma market
follow chang imbruvica ndc nation drug code iqvia report doubl count rx
one distributor late march continu part year
figur invokana franchis continu lose share
figur zytiga erleada monthli volum growth trend
rx y/i present canva data ada meet -posit efficaci safeti trade-off strengthen warn risk acut kidney add black box warn leg foot amput market share invokana invokamet jardianc synjardi glyxambi azn farxiga xigduo growthmonthli trxtrx growthtrx volumezytiga latitud data jun launch feb johnson johnson
new oral anticoagul includ pradaxa xarelto eliqui savaysa
 nrxnrxoral anticoagulantsnew oral anticoagul new oral anticoagul xarelto spaf approvedeliqui spaf approvedsavaysa spaf approvedeliqui dvt treatment approvedxarelto dvt treatment approvedeliqui dvt prevent growthim sale sustenna trinza consta sale yoy im sale growthsustenna launch aug launch jun market sharealk aristadaotsuka abilifi maintenajnj sinvega sustenna trinza risperd consta johnson johnson
figur opsumit trx iqvia sale trend
figur tracleer trx iqvia sale declin due gener competit
figur uptravi trx iqvia sale remain solid launch trajectori
sale trxtrxim sale trxtrxim salesjun start gener sale trxtrxim sale johnson johnson
price target
price target impli ep base sum-of-the-part
analysi risk includ unknown durationext impact uncertainti on-going opioid/talc
litig pipelin delay unexpect deterior industri
expect underli growth improv time eas multipl headwind new
johnson johnson world comprehens broadli base healthcar compani
consum pharmaceut medic devic market medic devic segment consist primarili
product intervent orthoped surgic vision compani report sale
underli growth year-over-year
